Nexalin Technology, Inc. (NXL) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nexalin Technology, Inc. on September 19, 2024, covering events occurring on September 16, 2024. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbols NXL (Common Stock) and NXLIW (Warrants). Nexalin is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Carolyn Shelton as Senior Vice President of Quality, Regulatory and Clinical Affairs, effective September 16, 2024. Ms. Shelton brings prior experience from Openwater Health, Advanced Sterilization Products, and Medtronic.
Compensation and Management Commentary
Nexalin entered into a Letter Agreement with Ms. Shelton outlining the following compensation structure:
- Base Salary: $300,000 annually.
- Discretionary Bonus: Up to $40,000 annually based on performance milestones.
- Equity Grant: Stock options with a value of $60,000 (subject to Board approval and milestone achievement) under the 2023 Equity Incentive Plan.
- Vesting Schedule: Options vest equally over a three-year period beginning September 16, 2025.
The filing states there are no family relationships between Ms. Shelton and current directors or officers, and no other undisclosed arrangements exist.
Investor Verification Checklist
- Verify the final approval of the $60,000 stock option grant by the Board of Directors.
- Review the specific performance milestones required for the discretionary bonus and equity vesting.
- Confirm the impact of this new executive appointment on the company's regulatory and clinical strategy.
- Check subsequent filings for any updates to the company's financial position, as this 8-K contains no financial data.